IONS Jun 2024 60.000 call
| Previous Close | 0.4000 |
| Open | 0.4000 |
| Bid | 0.0000 |
| Ask | 0.7500 |
| Strike | 60.00 |
| Expire Date | 2024-06-21 |
| Day's Range | 0.4000 - 0.4000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 33 |
ZacksIonis (IONS), Biogen Down on Ending Development of ALS Drug
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
- Reuters
REFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drug
Biogen and Ionis Pharmaceuticals said on Thursday they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after failing to show improvement in patients in an early-to-mid stage study. Shares of Biogen and Ionis were each down nearly 2% in premarket trading. This marks another setback in the search for new treatments for ALS, a rare neurodegenerative disease that affects the voluntary control of limbs and leads to breathing trouble.
GlobeNewswireBiogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire studyBiogen and Ionis continue their long-standing commitment to developing therapies for ALS given the devastating impact of this progressive, fatal neurodegenerative condition CAMBRIDGE, Mass. and CARLSBAD, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) anno
